Inclusion criteria. Age less than 14 years old at the diagnosis - Diagnosis of CRS - Parents agree to the study by signing informed consent Exclusion criteria - Age more than14 years old at the diagnosis - Diagnosis of positional cranial deformity - Parents disagree to participate Categorical variables will be reported as numbers (percentage). Continuous non-parametric variables will be presented as median (interquartile range), and continuous parametric variables as mean and standard deviation. Differences between groups will be compared by chi-square or Xxxxxx'x exact tests for categorical variables, the Xxxx-Xxxxxxx and the Xxxxxxxx rank-sum test for continuous non-parametric variables. Paired and unpaired t-test for continuous parametric variables. Statistical significance will be set at a p-value <0.05. Importantly, both unit1 and 2 dispose of facilities with experts in the field of statistics and health data analytics: Laboratory of Statistics and bioinformatics for Unit-2.
Inclusion criteria. Age ≥ 18 years - Informed consent - refusal of informed consent - participation in controlled trials on pulmonary embolism As this is a non-interventional study, no additional inclusion/exclusion criteria apply. A simultaneous participation in any other non-interventional study/registry is allowed. No other explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.
Inclusion criteria. Each patient must meet all of the following inclusion criteria to be enrolled in the study: - voluntary written informed consent obtained before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care; - Patients with unresectable, advanced or metastatic neuroendocrine well differentiated GEP- NET (pancreatic NET (G2-G3), Small Intestinal NET, stomach NET, rectum NET) with Ki67 - Patients with unresectable, advanced or metastatic neuroendocrine well differentiated thoracic NET (typical and atypical lung NET, thymus NET) - Patients with unresectable, advanced or metastatic neuroendocrine well differentiated unknown primary NET with Ki67 ≥ 10%. - Locally advanced or metastatic disease documented as progressive by RECIST v1.1. on CT- scan or MRI at baseline and within 12 months prior to baseline. - disease that is not amenable to surgery with curative intent; - presence of at least one measurable target lesion for further evaluation according to RECIST v1.1; - age ≥18 years; - eastern Cooperative Oncology Group (ECOG) performance status 0 or 1(see APPENDIX I) - Octreoscan and/or PET 68Ga positive and/or IHC for SSTR2; - Prior PRRT therapy must be completed at least 6 months prior to enrollement; - Advanced GEP, thoracic and unknown origin NET limited to the treatment of patients naïve or who have received a previous therapy for advanced disease or maximum 2 lines if any of these regimens include treatment with somatostatin analogs previously administered for a short period of time (less than 12 months for Octreotide and less than 6 months for Lanreotide) - Prior treatment with somatostatin analogs, biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, and/or radiation must be completed at least 28 days prior to registration; - Prior treatment with hepatic artery embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies must be completed at least 28 days prior to registration; - Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade 1 or less; - Patients must have completed any major surgery at least 2 months prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior t...